|
Market Closed -
Nasdaq
16:00:00 2026-09-30 EDT
|
5-day change | 1st Jan Change | ||
| 15.33 USD | -1.60% |
|
-7.15% | -15.58% |
| 09-20 | Avalo Therapeutics, Inc.(NasdaqCM:AVTX) added to S&P Global BMI Index | CI |
| 08-19 | Avalo Therapeutics Insider Sold Shares Worth $1,450,419, According to a Recent SEC Filing | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Bio Therapeutic Drugs
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 836M | - | - | - | - | - |
| 71.53B | |||||
| 60.12B | |||||
| 48.85B | |||||
| 44.28B | |||||
| 43.83B | - | - | - | - | - |
Select your edition
All financial news and data tailored to specific country editions
